Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma

Ibrutinib has demonstrated high response rates in B-cell lymphomas but a lot of ibrutinib-treated patients relapse with resistance. This study unified TME-mediatedde novoand acquired drug resistance through B-cell receptor signalling and PI3K-AKT-mTOR axis and provides a combination therapeutic stra...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Xiaohong Zhao, Tint Lwin, Ariosto Silva, Bijal Shah, Jiangchuan Tao, Bin Fang, Liang Zhang, Kai Fu, Chengfeng Bi, Jiannong Li, Huijuan Jiang, Mark B. Meads, Timothy Jacobson, Maria Silva, Allison Distler, Lancia Darville, Ling Zhang, Ying Han, Dmitri Rebatchouk, Maurizio Di Liberto, Lynn C. Moscinski, John M. Koomen, William S. Dalton, Kenneth H. Shain, Michael Wang, Eduardo Sotomayor, Jianguo Tao
Format:	article
Langue:	EN
Publié:	Nature Portfolio 2017
Sujets:	Science Q
Accès en ligne:	https://doaj.org/article/87b74c23a81c4b28a5b297ad5bef630b
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma

Documents similaires